Globus Medical, Inc. (GMED) Stock Analysis
Healthcare · Medical Devices
Wait — supporting gate not met yet. Price is at or below entry $77.71 but weak momentum still blocks BUY_NOW. Key risks: Leverage penalty (D/E 2.5): -1.5; Negative momentum.
Globus Medical is a musculoskeletal solutions company designing and selling spine, trauma, and enabling technology products — including surgical robots (ExcelsiusGPS) — to hospitals and surgical facilities globally. It earns revenue through direct and distributor-based device... Read more
Wait — supporting gate not met yet. Price is at or below entry $77.71 but weak momentum still blocks BUY_NOW. Key risks: Leverage penalty (D/E 2.5): -1.5; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 7.0/10, moderate confidence.
Passes 8/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.35, news boost analyst cluster(7), earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — Globus Medical, Inc.
Latest news
- NEWS Globus Medical (GMED) Stock: Technical Signals Overview | Q4 2025: Better Than Expected - Acquisition - Newser — Newser positive
- NEWS Globus Medical (GMED) Stock: Technical Signals Overview | Q4 2025: Better Than Expected - Crowd Breakout Signals - Newse — Newser positive
- NEWS Down 13.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Globus Medical (GMED) - MSN — MSN negative
- NEWS Globus Medical (GMED) Q1 earnings preview: What you should know beyond the headline estimates - MSN — MSN neutral
- NEWS How Upgraded Estimates and Zacks Rank #1 Status Will Impact Globus Medical (GMED) Investors - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait — supporting gate not met yet. Price is at or below entry $77.71 but weak momentum still blocks BUY_NOW. Key risks: Leverage penalty (D/E 2.5): -1.5; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $95.70 (+24.3%), stop $72.71 (−5.9%), Setup A.R:R 4.3:1. Score 7.0/10, moderate confidence.
Take-profit target: $95.70 (+28.5% upside). Target $95.70 (+24.3%), stop $72.71 (−5.9%), Setup A.R:R 4.3:1. Stop-loss: $72.71.
Leverage penalty (D/E 2.5): -1.5; Negative momentum.
Globus Medical, Inc. trades at a P/E of 18.8 (forward 15.6). TrendMatrix value score: 7.7/10. Verdict: Buy (Wait for Entry).
21 analysts cover GMED with a consensus score of 3.9/5. Average price target: $110.
What does Globus Medical, Inc. do?Globus Medical is a musculoskeletal solutions company designing and selling spine, trauma, and enabling technology...
Globus Medical is a musculoskeletal solutions company designing and selling spine, trauma, and enabling technology products — including surgical robots (ExcelsiusGPS) — to hospitals and surgical facilities globally. It earns revenue through direct and distributor-based device sales, with approximately 80% from the U.S. market following its 2023 NuVasive merger.